5-正丁基噻吩-2-羧酸 | 63068-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-正丁基噻吩-2-羧酸
• 中文别名: 5-丁基噻吩-2-羧酸
• 英文名称: 5-n-butylthiophene-2-carboxylic acid
• 英文别名: 5-Butyl-2-thiophenecarboxylic acid；5-Butyl-2-thiophencarbonsaeure；5-n-Butyl-thiophene-2-carboxylic acid；5-Butylthiophene-2-carboxylic acid
• CAS: 63068-74-6
• 化学式: C₉H₁₂O₂S
• 分子量: 184.259
• InChiKey: ZIPCXUIHYUTKFR-UHFFFAOYSA-N

物化性质

• 沸点：
  311.6±30.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-正丁基噻吩-2-羧酸 生成 5-丁基-2-噻吩甲酰氯
  参考文献：
  名称：

  Kossmehl, Gerhard; Budwill, Detlev, Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1983, vol. 38, # 12, p. 1669 - 1677

  摘要：

  DOI：
• 作为产物：
  描述：

  2-噻吩甲酸 、 正丁醇 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.17h， 以68%的产率得到5-正丁基噻吩-2-羧酸
  参考文献：
  名称：

  Novel S1P₁ Receptor Agonists - Part 2: From Bicyclo[3.1.0]hexane-Fused Thiophenes to Isobutyl Substituted Thiophenes

  摘要：

  Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P(1), receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head. In a first step the bicyclohexane moiety could be replaced by a simpler, less rigid cyclohexane ring without compromising the SIP receptor affinity profile of these novel compounds. In a second step, the thiophene head was simplified even further by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position S of the thiophene. These structurally much simpler headgroups again furnished potent and selective S1P(1) agonists (e.g., 87), which efficiently and dose dependently reduced the number of circulating lymphocytes upon oral administration to male Wistar rats. For several compounds discussed in this report lymphatic transport is an important route of absorption that may offer opportunities for a tissue targeted approach with minimal plasma exposure.

  DOI：

  10.1021/jm401456d

文献信息

• Thiophene derivatives as S1P1/EDGE1 receptor agonists
  申请人：Bolli Martin

  公开号：US20100048648A1

  公开（公告）日：2010-02-25

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  这项发明涉及新型噻吩衍生物，其制备以及作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。
• Pyrrolidin-2-One Derivatives for Use as Dp1 Receptor Agonists
  申请人：Araldi Luca Gian

  公开号：US20080027126A1

  公开（公告）日：2008-01-31

  The present invention is directed to compounds that may be used as agonists of prostaglandin receptors. More specifically, the specification describes methods and compositions for making and using DP1 receptor agonists that are pyrrolidin-2-one derivatives.

  本发明涉及可用作前列腺素受体激动剂的化合物。更具体地，本说明书描述了制备和使用吡咯烷-2-酮衍生物的DP1受体激动剂的方法和组合物。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP3175852A1

  公开（公告）日：2017-06-07

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  本文公开了通过施用式 (I) 化合物治疗牡蛎性骨质疏松症、骨折、骨质流失和增加骨密度的组合物和方法。 或包含式（I）化合物和药学上可接受的载体的组合物，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。
• DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP3176162A1

  公开（公告）日：2017-06-07

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  此处公开的是式 (I) 化合物 以及用式（I）化合物进行治疗的方法，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式（I）化合物是 EP4 激动剂，可用于治疗青光眼、神经性疼痛及相关疾病。
• Kossmehl, Gerhard; Budwill, Detlev, Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1983, vol. 38, # 12, p. 1669 - 1677
  作者：Kossmehl, Gerhard、Budwill, Detlev

  DOI：——

  日期：——